Aminophylline: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 1, 2026🚩 Report this page

Aminophylline

Xanthines

GB MHRACA Health Canada

Drug class: Xanthines
Availability: See label
Routes: Intravenous
Markets covered: 2
Products on record: 2

Overview

Aminophylline is an active pharmaceutical ingredient in the Xanthines group (R03DA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	May 1, 2026
CA Canada	Health Canada	1	March 22, 2025

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised May 1, 2026[1]

g. an adjunct in the treatment of pulmonary oedema or paroxysmal nocturnal dyspnoea caused by left ventricular heart failure), reversible airways obstruction including status asthmaticus and acute bronchospasm.

How to take

CACanada· Health Canada

1 product

1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].

Drug interactions

Known interactions involving Aminophylline. Select one for details. This list is informational and not a complete interaction checker.

Acebutolol Atenolol Betaxolol Bisoprolol Bupropion Carteolol Carvedilol Ciprofloxacin Deferasirox Enoxacin Esmolol Fluvoxamine Halothane Iohexol Iopamidol Labetalol Levobetaxolol Levobunolol Metipranolol Metoprolol Mexiletine Nadolol Nebivolol Penbutolol Pindolol Propranolol Riociguat Sotalol Timolol Tramadol Activated Charcoal Adalimumab Adenosine Albuterol Alefacept Amifampridine Aminoglutethimide Amiodarone Amobarbital Anakinra Arformoterol Atracurium Azithromycin Betamethasone Blinatumomab Budesonide Butabarbital Butalbital Canakinumab Cannabidiol Carbamazepine Certolizumab Pegol Cimetidine Cinoxacin Cisatracurium Clarithromycin Colesevelam Cosyntropin Demeclocycline Dexamethasone Diltiazem Dipyridamole Disulfiram Doxacurium Doxycycline Drospirenone Emapalumab Erythromycin Estradiol Etanercept Ethinyl Estradiol Ethotoin Etonogestrel Famotidine Febuxostat Fluconazole Fludrocortisone Fluphenazine Formoterol Fosphenytoin Golimumab Grepafloxacin Guselkumab Hydrocortisone Imipenem Indacaterol Infliximab Interferon Alfa-2b Interferon Alfa-N1 Interferon Alfa-N3 Interferon Alfacon-1 Interferon Beta-1a Interferon Beta-1b Interferon Gamma-1b Isoetharine Isoniazid Isoproterenol Ixekizumab Ketamine Levonorgestrel Levothyroxine Lindane Liothyronine Lithium Carbonate Mephenytoin Mephobarbital Metaproterenol Methimazole Methohexital Methylprednisolone Metocurine Metreleptin Minocycline Mivacurium Nizatidine Norethindrone Norfloxacin Norgestrel Obeticholic Acid Ofloxacin Olodaterol Oxytetracycline Pancuronium Peginterferon Alfa-2a Peginterferon Alfa-2b Peginterferon Beta-1a Pentobarbital Pentoxifylline Phenobarbital Phenytoin Picosulfurate Pipecuronium Pirbuterol Prednisolone Primidone Propafenone Propylthiouracil Ranitidine Rapacuronium Regadenoson Rifampin Rilonacept Ritodrine Ritonavir Rocuronium Rofecoxib Salmeterol Sarilumab Satralizumab Secobarbital Secukinumab Siltuximab Sodium Sulfate Stiripentol Succinylcholine Tacrine Terbinafine Terbutaline Tetracycline Thiabendazole Thiopental Ticlopidine Tocilizumab Triamcinolone Troleandomycin Tubocurarine Tucatinib Ustekinumab Vecuronium Verapamil Vilanterol Voxelotor Zafirlukast Zileuton Acyclovir Allopurinol Alprazolam Chlordiazepoxide Clobazam Clonazepam Clorazepate Diazepam Ephedrine Estazolam Felodipine Flurazepam Furosemide Halazepam Ketoconazole Lansoprazole Lorazepam Midazolam Moricizine Mycophenolate Mofetil Mycophenolic Acid Nifedipine Nisoldipine Oxazepam Propofol Quazepam Remimazolam Riluzole Roflumilast Sulfinpyrazone Temazepam Tocainide Triazolam Acetaminophen Alendronate Amphotericin B Aspirin Atropine Captopril Cefazolin Cefepime Cefotaxime Ceftazidime Cefuroxime Cisplatin Citalopram Clopidogrel Digoxin Dobutamine Enalapril Fentanyl Fluticasone Heparin Hydrochlorothiazide Ibuprofen Indomethacin Ketoprofen Lactulose Leflunomide Lidocaine Linezolid Lisinopril Loratadine Losartan Metoclopramide Metolazone

Showing 240 of 265. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL015020009 · revised May 1, 2026
[2]Health Canada (DPD) · 00582662 · revised March 22, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Aminophylline has a narrow therapeutic index, therefore cautious dosage determination is essential. Therapeutic serum concentrations of theophylline are considered to range from 10 to 20 micrograms/ml and levels greater than 20 micrograms/ml are often associated with toxic effects.
A range of 5 to 15 micrograms/ml may be effective, and associated with fewer adverse effects. The dosage should be titrated for each individual and adjusted with caution. Serum theophylline levels should be monitored to ensure that they remain within the therapeutic range.
During therapy, patients should be monitored carefully for signs of toxicity. Elimination of theophylline in children younger than 6 months of age, especially in neonates, appears to be reduced. Because of this variation in metabolism the use of Aminophylline injection in children under 6 months of age is not recommended.
Use in patients NOT currently receiving theophylline preparations To minimise adverse effects, IV Aminophylline should be administered slowly, at a rate not exceeding 25mg Aminophylline per minute, up to a dose of 250-500mg (5mg/kg).
If patients experience acute adverse effects while loading doses are being infused, the infusion may be stopped for 5-10 minutes or administered at a slower rate. b. The use of Aminophylline IV in children under 6 months of age is not recommended.
3mg/kg/hour Use in patients currently receiving theophylline preparations In patients who are currently receiving theophylline preparations, the time, route of administration and dosage form of the patient’s last dose should be determined where possible and considered in determining a loading dose.
5mg/kg (lean body weight) of theophylline will result in a 1 microgram/ml increase in serum theophylline concentration. Therefore, in patients currently receiving theophylline preparations, the loading dose should be deferred until a serum theophylline concentration can be attained or the clinician must carefully select a dose based on the potential benefits and risks.
Subsequently, the approximate IV aminophylline maintenance doses described above may be considered. Method of administration Aminophylline 25 mg/ml solution for injection/infusion may be given by slow intravenous injection or intravenous infusion in glucose injection or sodium chloride injection.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 1, 2026[1]

Adverse events are usually a consequence of gastrointestinal irritation, stimulation of the central nervous system and effects on the cardiovascular system. Hypotension, arrhythmias and convulsions may follow intravenous injection, particularly if the injection is too rapid, and sudden deaths have been reported.
Severe toxicity may occur without preceding milder symptoms (see also

GBOfficial regulatory label· Warnings and precautions· revised May 1, 2026[1]

2). Aminophylline has a narrow therapeutic index and serum levels should be monitored regularly, particularly during initiation of therapy. Aminophylline injection should be administered cautiously to patients over 55 years of age. Children are particularly susceptible to the effects of theophylline and care is required when administrating aminophylline to children.
There have been reports of seizures in children with theophylline plasma levels within the accepted therapeutic range. Alternative treatment should be considered in patients with a history of seizure activity and, if Aminophylline Injection is used in such patients, they should be carefully observed for possible signs of central stimulation.
Caution is also advised in patients undergoing influenza immunisation or who have active influenza infection or acute febrile illness. Aminophylline should be given with caution to patients with cardiac failure, chronic obstructive pulmonary disease, renal or hepatic dysfunction and in chronic alcoholism since clearance of Aminophylline is decreased.
Because the mean half-life of theophylline is shorter in smokers than in non- smokers, the former group may require larger doses of aminophylline. During regular therapy serum potassium levels must be monitored. This is essential during combination therapy with beta2-agonists, corticosteroids or diuretics, or in the presence of hypoxia.
Aminophylline should be used with caution in patients with peptic ulcer, hyperthyroidism, glaucoma, diabetes mellitus, severe hypoxaemia, hypertension, compromised cardiac or circulatory function and epilepsy, as these conditions may be exacerbated.
Methylxanthines may increase gastric acidity and care should be taken when they are used in patients with a history of peptic ulceration Aminophylline should not be administered concurrently with other xanthine medications.

This is not medical advice. Consult a qualified healthcare professional.